Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Oruka Therapeutics Inc. (ORKA)

NASDAQ: ORKA · Pharmaceutical Preparations · Menlo Park, CA

Our rating: Cautious

Call changed from Neutral to Cautious at $109.50, low conviction, November 10, 2026.

Breaks if: The Cautious call is wrong if the stock closes above $148 — roughly 35% above the current price — within six months (approximately 126 trading days), which would signal that a clinical readout, regulatory milestone, or partnership has validated the valuation in a way the current filings do not. It is also wrong if the company discloses a Phase 3-ready asset in a large indication with a near-term primary endpoint read, shifting the risk/reward clearly in the company's favor before the next two quarterly filings.

Key figures

Market value$6.5B
Revenue, last 12 monthsn/a
Net income, last 12 months−$153M
Free cash flow, last 12 months−$124M
Price to earningsn/a
Free cash flow yield−1.9%
Dividend yield0.0%
Operating marginn/a
Return on equity−18.1%
Beta to the S&P 5001.24
Volatility, annualized76.3%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/an/a−$44M
June 30, 2026n/an/an/a−$33M
March 31, 2026n/an/an/a−$24M
December 31, 2025n/an/an/a−$23M
September 30, 2025n/an/an/a−$22M
June 30, 2025n/an/a$-0.46−$23M
March 31, 2025n/an/a$-0.40−$21M
December 31, 2024n/an/a$2.21−$19M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

21 ledger entries and 112 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.